Longer Time Between Pre- And Postoperative Chemo Worsens Survival in Ovarian Cancer
Longer time in between pre- and postoperative chemotherapy may be associated with significantly worse survival outcomes in women with ovarian cancer.
BY Jason Harris
PUBLISHED December 05, 2017
Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.
Investigators in South Korea conducted a retrospective analysis of 194 women with pathologically confirmed epithelial ovarian cancer who received neoadjuvant chemotherapy at Yonsei Cancer Hospital in Seoul from 2006 to 2016. In the multivariate analysis, a longer interval to treatment initiation was associated with significantly poorer progression-free survival (PFS) and overall survival (OS).
The time interval was defined as the period from the completion of neoadjuvant chemotherapy, spanning interval debulking surgery (IDS), to the initiation of postoperative adjuvant chemotherapy.
“Our results demonstrate that a significant correlation may exist between survival outcomes and the time intervals between the completion of neoadjuvant chemotherapy and initiation of postoperative adjuvant chemotherapy, and that a delay in postoperative adjuvant chemotherapy initiation beyond 42 days after neoadjuvant chemotherapy may lead to worse survival outcomes,” corresponding author Jung-Yun Lee, M.D., and coinvestigators wrote.
“Further studies are warranted to validate our findings and to provide additional information on the relationships between neoadjuvant chemotherapy, the initiation of postoperative adjuvant chemotherapy, and the survival outcomes of the patients,” continued Lee and colleagues.
All patients were confirmed to have stage III or IV disease prior to starting chemotherapy. The median age was 57 years, and 91.8 percent had serous histology.
Eighty-two patients underwent radical surgery, including 30 who underwent bowel surgery. In 86 patients, there was no gross residual tumor present after IDS.
All patients received platinum-based combination chemotherapy. A total of 155 patients received paclitaxel plus carboplatin, and the median number of cycles of total chemotherapy was eight. About half of patients began postoperative treatment within the 42-day interval and 91 initiated after 42 days.
FIGO stage, non–high-grade serous carcinoma histology and any residual disease were independent prognostic factors associated with a higher risk of progression. For OS, multivariate analysis showed that a longer time interval was an independent prognostic factor in all patients. Furthermore, non–high-grade serous carcinoma histology and any residual disease were significantly associated with a higher risk of death. Residual disease was also found to be an independent prognostic factor associated with higher risks for progression and death.
Investigators separated patients into quartiles based on the time intervals to evaluate the presence of a linear trend. Patients with longer time intervals were found to have higher risks for recurrence and death. Patients in the highest quartile of more than 50 days had the highest risks of recurrence and death, as compared with patients in the lowest quartile of 37 days or less.